Stoller, Ronald
Schmitz, John C.
Ding, Fei
Puhalla, Shannon
Belani, Chandra P.
Appleman, Leonard
Lin, Yan
Jiang, Yixing
Almokadem, Salah
Petro, Daniel
Holleran, Julianne
Kiesel, Brian F.
Ken Czambel, R.
Carneiro, Benedito A.
Kontopodis, Emmanuel
Hershberger, Pamela A.
Rachid, Madani
Chen, Alice
Chu, Edward
Beumer, Jan H.
Funding for this research was provided by:
National Cancer Institute (U01CA099168, UM1CA186690, P30CA047904)
Hellenic Society of Medical Oncology
Article History
Received: 10 July 2017
Accepted: 27 July 2017
First Online: 2 August 2017
Compliance with ethical standards
:
: This study was supported in part by NCI grants U01CA099168 and UM1CA186690. This project used the UPCI Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) and was supported in part by award P30CA047904. The project described was supported by the National Institutes of Health through Grant Number UL1TR001857. EK was supported by a scholarship from the Hellenic Society of Medical Oncology.
: Jan Beumer received research support from AbbVie. Shannon Puhalla has received research support from AbbVie, Pfizer, Lilly, Novartis, Incyte, Covance-Bayer, AstraZeneca, Genentech, Medivation and has been a consultant for AbbVie, MedImmune, Celldex, Puma, Pfizer, AstraZeneca, Esai, nanostring.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This trial was registered under ClinicalTrials.gov Identifier: NCT01154426.
: Informed consent was obtained from all individual participants included in the study.